Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder
Source: BioPharma Dive - Latest News
The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate.